Last updated on November 2017

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease


Brief description of study

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

Detailed Study Description

The study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.

Clinical Study Identifier: TX8646

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jennifer Cavin

NeuroStudies.net, LLC
Decatur, GA USA
  Connect »